Recent years have witnessed intensive progress in studying extracellular vesicles (EVs), both for understanding their basic biology and contribution to variety of diseases, biomarker discovery, and their potential as gene delivery vectors and source of innovative therapies. As such, stem cell-derived EVs have contributed significant knowledge which led to the development of cell-free therapies in regenerative medicine. Although, the role of stem cell-derived EVs in maintaining stemness, differentiation and repairing tissue injuries is relatively well-understood; however, knowledge about the contribution of stem cellderived EVs in cancer progression is just emerging. The aim of this review is, therefore, to discuss the recent developments in stem cell-derived EVs and tumor progression, placing a particular focus on noncoding RNA (ncRNA) mediated cancer progression and resistance against therapies. This includes the failure of normal hematopoiesis and the progression of myeloid neoplasms, enhanced capacity of cancer cells to proliferate and metastasize, and the conversion of normal cells into cancer cells, activation of angiogenic pathways and dormancy in cancer cells. These processes are shared by mesenchymal stem cells (MSCs), cancer stem like-cells and cancer cells in an intricate intratumoral network in order to create selfstrengthening tumor niche. In this context, EV-ncRNAs serve as mediators to relay bystander effects of secreting cancer stem cells (CSCs) into recipient cells for priming a tumor permissive environment and relaying therapeutic resistance. Collectively, this knowledge will improve our understandings and approaches in finding new therapeutic targets in the context of CSCs, which could be benefited through engineering EVs for innovative therapies.
Introduction
Stem cells are a class of undifferentiated pluripotent cells with substantial ability to self-renew and differentiate into variety of specialized cell types. Characteristically, stem cells are best known for their contribution in developmental processes and maintaining the regenerative programs for the body. However, defined populations of biologically discrete cells-so called cancer stem cells (CSCs) (1), could be responsible for initiating malignancy (that will be discussed in later sections). Understanding stem cell biology fully, is essential for gaining mechanistic insights into human diseases and their effects in regenerative process. The current applications of stem cells in translational medicine rely largely on their potency for repairing tissue damages and ameliorating organ functions. In this context, the best characterized are the mesenchymal stem cells (MSCs). According to the International Society for Cellular Therapy (ISCT), the MSCs are defined as plastic adherent cells with the capacity to differentiate into osteoblasts, chondrocytes, myocytes and adipocytes (2) . The commonly considered sources of MSCs are bone marrow, adipose tissue, the umbilical cord, nervous tissue, dental pulp, amniotic fluid, the placenta, and menstrual blood (3, 4) . MSCs derived from these sources represent remarkable differences in morphology, proliferation, self-renewal ability and differentiation potential (2) . Importantly, their capacity to differentiate towards osteoblasts, chondrocytes, myocytes and adipocytes, their ability to be activated during injury and colonization to injury site offer a promising source in tissue regeneration. The benefits of stem cellbased therapies are evident from their success in improving the symptoms of many diseases; including, diabetes, osteoarthritis, spinal cord injury, myocardial injury, graft versus host disease, and bone repair shown in many clinical and preclinical models (5) .
In addition to their characteristic functional attribution in regenerative process, the stem cells have also been implicated in cancer initiation and therefore, are designated as CSCs (1) . CSCs possess substantial potential for clonal tumor initiation, long-term repopulation, and phenotypic plasticity preservation (6, 7) . A number of cell surface markers, such as CD34, CD133, CD24, CD44, CD166, and epithelial cell adhesion molecule (EpCAM), are used to identify and enrich CSCs from several types of cancers (1) . Although, the origin of CSCs and the prediction of their biological activity remained a debated issue (1, 8) ; and have been explained through CSC model (also known as a hierarchical model). This model posits that a defined population of biologically discrete cells is distinctively responsible for initiating malignancy (9) , and that the tumor population is hierarchically arranged (10) . Subsequently, the tumorinitiating activity can be enriched by sorting cells on the basis of intrinsic characteristics and may be prospectively isolated based on a specific cell surface marker (11) .
Conversely, the stochastic model of cancer posits that all of the cells within a cancer have equal potential to act as cancer-initiating cells (CICs) with a potential to propagate the cancer [reviewed in (1) ]. According to this model, tumor-initiating activity cannot be improved by sorting cells based on intrinsic characteristics and cannot be prospectively determined based on the local environment in which cells reside. This model assumes that the activities of CICs are governed by re-entry into the cell cycle, which is in fact a low-probability stochastic event, making it impractical to realistically identify the tumor-initiating subset.
Importantly, the secreted paracrine factors could play critical role in mediating crosstalk between the elements of the local stroma (microenvironment) and stem cells, whereby the cells may assertively orchestrate themselves in a given tumor niche and may exchange genetic material. The exchanges of biological material are vital to cancer development and could, therefore exhibit several features of CSCs (8) . In this regard, the exchange of CSC-derived secretome with distinct CSC signatures presumably originated from different stem cell hierarchies could represent several features of their originating cells. Therefore, it is arguable that paracrine trophic factors originated from CSCs may reflect and recapitulate CSC features.
Recent body of evidence suggest that normal stem cells as well as the CSCs secrete small vesicles called extracellular vesicles (EVs), which serve as novel means of stem cellderived paracrine trophic factors (12) . EVs are nano-and micro-sized vesicles that are ubiquitously produced from many perhaps all cell types under normal and pathological conditions. In fact, EVs are classified into heterogeneous populations of secreted vesicles (13) (14) (15) (16) . Among these, best characterized are the exosomes which are originated and produced via endocytic/exocytic pathway; and the microvesicles which bud off directly from the plasma membrane [for detailed mechanisms of biogenesis see (17) ]. During their biogenesis, EVs are endogenously packaged with a repertoire of bioactive molecules such as proteins, transcriptional factors, lipids, carbohydrates, and nucleic acids including DNA, coding-and non-coding RNAs (ncRNAs) [reviewed elsewhere (18) ]. Since these secreted vesicles transport bioactive molecules and disseminate biological signals, they act as mediators of intercellular communication between neighboring cells (16, 19, 20) , or bridging cellular channels between cells located apart (21) . EVs could also transport their cargo particularly the circulating miRNAs to the cells of distant organs and may confer long distance inter-organ communication and metabolic regulation (22, 23) .
Most commonly reported stem cells that secrete EVs include, embryonic stem cells (ESCs) and adult stem cells of different origins such as bone marrow mesenchymal stem cells (BMMSCs), adipose stem cells (ADSCs), human liver stem cells (HLSCs), induced pluripotent stem cells (iPSCs), and other tissue specific stem cells [reviewed in (12) ]. It has been reviewed that EVs secreted from these stem cell sources potentially mimic the features of their secreting stem cell and are widely recognized as evolving factors in stem cell biology (12) . The most frequently reported are the MSCs-derived EVs with potential therapeutic effects in tissue regeneration and organ healing (24) (25) (26) (27) (28) (29) .
Although, much has been documented about their participation in repair processes (29) ; less is known about how stem cell-derived EVs (from both normal stem cells and CSCs) contribute in cancer progression and mediate resistance to therapies. This review will, therefore, provide a detailed summary of recent developments of stem cell secreted EVs in tumor progression as well as tumor inhibition with mechanistic insights into stem cells, EVs, ncRNAs and intratumoral networking.
RNA in stem cell derived EVs: implications in stem maintenance and differentiation
Increasing body of evidence support that EVs mimic several features of their parent cells and have a profound effect on stem cell fate decisions (12) . This includes the presence of bioactive molecules in EVs and their delivery between cells. However, the most profound paracrine regulatory effects of stem cell-derived EVs are elicited by transporting RNA species (30) (31) (32) (33) (34) . First evidence was reported by Ratajczak and colleagues in 2006, which revealed that stem cellderived EVs contain mRNA transcripts for pluripotent transcriptional factors such as Nanog, Oct-4, HoxB4, and Rex-1, which can be horizontally transferred between cells, and favor the hematopoietic progenitor cells' expansion (35) . Quesenberry and colleagues proposed that EV-mediated communication and exchange of genetic material is the continuum model of stem cell biology, where the differentiation decision of stem cells is conditioned by the cell cycle transit and the environmental stimuli (36) . Stem cells help keeping population equilibrium between undifferentiated and the differentiated mature cells. This implies that the deficiency of differentiated mature cells in a particular tissue could be sensed by progenitors, which produce more progenies to be differentiated into mature cells. Such equilibrium could be facilitated by EV-mediated bidirectional exchange of genetic material, which favors stem cell populations to maintain a stable co-existence (12) .
Stem cell-derived ncRNA
Stem cell-derived EVs not only transport coding RNA (i.e., mRNA), but also ncRNA species, which recapitulate the stem cell properties of their originating stem cells and serve as stem cells' extended paracrine messengers in maintaining stem cell features (37) . It has been shown that MSCderived EVs are enriched in distinct ncRNA species such as miRNAs, tRNA and Piwi-interacting RNA (piRNAs), which contribute in maintaining stem cell potency (38) , induction of cell survival and regulation of cell differentiation of cord blood hematopoietic stem cells (39) . The comparison of transcriptomic (RNA-Seq) and proteomic profiles of ESCderived EVs and EVs from human BMMSC revealed distinctly different RNA profiles between EVs of two stem cell populations (40) . The secretion of selective pattern of miRNAs from stem cells and their transfer to target cells via EVs raises enormous potential for stem cells to recapitulate lineage specific characteristics (41, 42) .
Since ncRNAs are central to gene regulation and cellular fates, it can be speculated that most of the EV-mediated regulatory roles elicited in cells/organs are mediated through ncRNAs (18, 37) . Indeed, ncRNAs are expressed in tissue-specific manner, precisely regulated and actively involved in variety of developmental processes (43) (44) (45) (46) (47) (48) (49) (50) , and the lineage specific commitments of stem cells and the maintenance of their characteristic features such as pluripotency, self-renewal, differentiation, and efficiency of cellular reprogramming are largely regulated by ncRNAs (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) . Thus, the ncRNAs may govern the equilibrium between pluripotency and differentiation in stem cells, as well as lineage specific fate decisions (61, 62) . (63) . Likewise, ESC-derived EVs could transport selective subset of miRNA and transcriptional factor related mRNAs which may induce pluripotency in their target cells and turn on early retinogenic program of differentiation (64) . EVs could also contribute in hematopoietic progenitor cell mobilization through EV-mediated transfer of miRNAs which downregulate vascular cell adhesion molecule (VCAM1) expression (65) . Altogether, these studies support the idea that stem cells have evolved mechanisms for maintaining stem cell specific features at least, in part through EV-mediated dissemination of ncRNAs.
derived EVs in tumor progression [reviewed in (1, (66) (67) (68) ]; however, the role of stem cell-derived EVs carrying ncRNAs in cancer progression are only recently begging to be explored. Several layer of evidence has clarified that tumor initiation and progression through EV-mediated transport of abnormally expressed miRNAs could regulate oncogenic pathways (69) (70) (71) (72) (73) . As such, EV-mediated dissemination of miRNAs may consequently contribute to the construction of premetastatic niche, metabolic reprograming, and the modulation of tumor microenvironment (68, 70, (74) (75) (76) (77) (78) .
It has been argued that EVs originated from normal stem cells possess regenerative properties, whereas those secreted from CSCs exhibit cancer-associated activities (1, 66, 67, 79) . However, recent reports claim that EVs from normal stem cells could also have a profound effect on cancer progression and this is largely due to genetic content that is being disseminated and the conditions primed by stem cellderived EV-ncRNAs in recipient cells. As such, miRNAs and long non-coding RNAs (lncRNAs) disseminated from stem cells to cancer cells or from cancer cells to stem cells could induce bystander oncogenic affects in recipient cells and induce metastatic behaviors.
Mechanisms

EV-miRNA dissemination and bystander effects
It has been shown that MSCs express tumor supportive miRNA such as miR-21, and miR-34a that are secreted via EVs and delivered to cancer cells. The co-incubation of EVs with breast cancer cells in vitro allowed the enhanced angiogenesis and favored the cancer metastasis in recipient cells, whereas in vivo co-injections of EVs along breast cancer xenograft permitted the enhanced tumor size in a xenograft model (80) . These effects were shown by EVmediated delivery of miRNAs. Glioma stem cells-derived EVs have also been shown to promote the angiogenic ability of endothelial cells through activation of miR-21/VEGF signaling pathway (81) . Similarly, MSC-derived EVs could deliver miR-221 into human gastric cancer cells and modulate gene expression thereby allowing the proliferation and migration of recipient cancer cells (82) . Interestingly, although EV-encapsulated miRNAs from prostate cancer bulk and CSCs reflect distinctly differential patterns; yet act cooperatively in cancer metastasis (83) .
More lately, it has been reported that the miR-7977 in EVs is responsible for the hematopoietic dysfunctioning of MSCs by reducing the levels of poly(rc) binding protein 1 in myeloid neoplasms (84) . This failure of normal hematopoiesis is subsequently linked with the progression of myeloid neoplasm. This is important to note that EVs are not only transferred from stem cells to cancerous cells but could also be delivered from cancer cells to stem cellsa reciprocal transfer. For instance, multiple myeloma (MM) cells were shown to deliver miR-146a into MSCs via EVs, which resulted into elevated level of cytokine secretion, which in turn created a conducive environment to facilitate cell viability and migration of MM cells (85) . It has been shown that adult T-cell leukemia/lymphoma (ATL) cellderived EVs could deliver Tax, vascular endothelial growth factor (VEGF), and leukemia-related miRNAs such as miR-21 and miR-155 to MSCs, which alter their properties to create a more conducive milieu for leukemia (86) . These both reports indicate the contribution of EVs in positive feedback loop between cancer cells and MSCs in order to favor tumor growth.
Recently, Kumar et al., has revealed that acute myeloid leukemia (AML) cells transform/remodel the bone marrow niche into a leukemia-permissive microenvironment through EV secretion and the downregulation of hematopoietic stem cell supporting factors (i.e., preparation of normal-hematopoiesis-suppressive microenvironment) (87) . Engrafted AML-derived EVs or pre-conditioning with AML-derived EVs efficiently increased the MSC progenitors, blocked osteolineage development and bone formation in vivo and 'primed' the animals for accelerated AML growth. In addition, AMLderived EVs induced downregulation of hematopoietic stem cell supporting factors such as CXCL12, KITL, and IGF1 in BMMSC and reduced their ability to support normal hematopoiesis (87) . Altogether, this study uncovers novel features of AML pathogenesis and unveils how AML cells create a self-strengthening leukemic niche that promotes leukemic cell proliferation and survival, while suppressing normal hematopoiesis through EV secretion.
Networking between stem-like cells' subpopulations: heterogeneous intra-tumoral ecosystem
Recent body of evidence suggests that EVs and miRNAs convey biological material that could rearrange the molecular landscape within the heterogeneous intratumoral ecosystem in a cell type-specific manner as shown by characterization of miRNA secretion in phenotypically diverse subpopulations of glioblastoma stem-like cells (GSCs). It was shown that the intratumoral exchange of miRNA could augment the heterogeneity of patient-derived GSCs. This was reflected in highly heterogeneous profile of miRNA expression in GBM subtypes (88) . Moreover, it was reported that the expression of the subtype-enriched miRNAs such as miR-128 within transcriptionally and phenotypically diverse subpopulations of patientderived GSCs is a potent mechanism of bidirectional transitions between GBM subpopulations (89) . This could consequently result in intermediate hybrid stages, highlighting highly intricate intra-tumoral networking. In addition to persistence of intra-tumoral heterogeneity, the loss of subtype characteristics in the tumor initiating cell compartment may contribute potent role in therapeutic resistance. This was shown in a recent study by Rak and colleagues where individual tumors derived from the same isogenic GSC line were able to express divergent and complex profiles of temozolomide resistance markers (90) . Authors concluded that intrinsic changes in the tumor initiating cell compartment may include loss of subtype characteristics and reciprocal alterations in sensitivity to chemo-and radiation therapy. This divergent evolution of chemo-resistance is reflected in EVs (90) .
Recently, Figueroa et al., has reported that glioma associated-human MSCs (GA-hMSCs)-derived EVs facilitate tumor supporting activities of GSCs by transferring glioblastoma specific miR-1587 between cells (91). Additionally, the comparison of miRNA content of EVs isolated from breast patients revealed stem cell-like properties and metastatic signature from patients with worse prognosis (92) . This data supports the view that cancer cells with stem-like properties and their EVs could potentially aggravate tumor progression and metastasis.
Resistance to chemotherapies and tumor progression
Emerging studies indicated that CSCs represent a subpopulation of cells within the tumor that is responsible for chemotherapeutic resistance. In this context, one of the emerging roles of stem cell-derived EVs is their contribution to mediate cancer cell resistance against therapies (18) , and promote tumor growth. The most propelling examples are those observed from MSCs. It has been recently demonstrated that breast cancer cells educate MSCs to release EVs with distinct miRNA content, such as miR-222/223, which promotes quiescence in a subset of cancer cells and confers drug resistance (93) . In an immunodeficient mouse model of dormant breast cancer, the systemic administration of MSC-derived EVs loaded with antagomiR-222/223 efficiently sensitized breast cancer cells to carboplatin-based therapy and increased host survival. This indicates the role of EV-miRNA to mediate regulatory interactions between MSCs and breast cancer cells in the evolution of tumor dormancy and resurgence in the local metastatic microenvironment (93) . Interestingly, this approach may favor the development of nontoxic therapeutic strategy to target dormant breast cancer cells for enhancing drug sensitivity and tumor monitoring. C a n c e r c e l l d e r i v e d E V-m i R N A s h a v e b e e n implicated in the maintenance of stem cell property and chemotherapeutic resistance in cancer cells. For instance upregulation of miR-196b-5p in colorectal cancer (CRC) tissues enhances the spheroids formation ability, the fraction of stem-like subpopulations and the expression of stem cell factors (94) . Moreover, miR-196b-5p is highly enriched in the serum EVs of patients whereby elevated expression of miR-196b-5p promotes stemness and chemoresistance of CRC cells against 5-fluorouracil via targeting SOCS1 and SOCS3 of STAT3 signaling pathway, and subsequent activation of STAT3 signaling pathway.
MSCs-derived EVs contain over expressed miRNA-23b, which promotes dormancy in metastatic breast cancer cells by suppressing MARCKS target gene (95) . EVs transfer miRNAs to breast cancer cells which could potentially regulate chemoresistance in recipient cancer cells as well as in CSCs (96) . In another example, the miRNAs from cancer-associated adipocytes and cancer associated fibroblasts could be transported to ovarian cancer cells via EVs, which confer paclitaxel resistance by suppressing apoptotic peptidase activating factor 1 (APAF1) in recipient cancer cells (97) . In addition to their contribution as mediators of chemoresistance, EVs may also facilitate chemosensitivity in cancer cells. EVs derived from AD-MSCs are implicated in promoting chemosensitivity in HCC and favor antitumor efficacy of chemotherapeutic agents in recipient cancer cells (98) . The AD-MSCs transfected with miR-122, tether miRNA into EVs, that is taken by HCC upon co-incubation of EVs with HCC cells and promotes increased sensitivity to chemotherapeutic agents (98) . Collectively these studies could offer a potential rational for combining EV-mediated anti-miRNA strategies with conventional chemotherapy against cancer.
LncRNAs in stem cell-derived EVs and tumor progression
Although, the role of EV-associated lncRNAs from various cell types has been demonstrated in the progression of cancer and resistance to therapies (18) ; however, there is limited knowledge about the contribution of stem cellderived EV-lncRNAs in cancer progression. Recent studies demonstrate that lncRNAs in EVs are transferred in both directions i.e. from stem cells to cancer cells as well as from cancer cells to stem cells and act differently in cancer progression. For instance, CD90 + liver cancer cells modulate endothelial cell phenotype and promote angiogenesis through EV-contained H19 lncRNA (99) . However, EVs from parental hepatoma cells lacking CD90 do not exhibit such features, indicating that such features of EV-linked H19 are exclusive to CD90 + cancer stem-celllike cells. Conversely, cancer cells may transfer lncRNA molecules to stem cells and modulate their behaviors. For example, MSCs treated with lung cancer-derived EVs revealed that EVs from cancer cells could initiate global changes in lncRNA expression in MSCs (100) .
Anti-tumor effects of stem cell-derived EV-miRNAs and tumor inhibition
Interestingly, in addition to their participation in cancer progression, the stem cell-derived EV-miRNAs are well appreciated for their contribution in tumor inhibition. For instance, EVs from a conditioned medium of AD-MSCs could induce apoptosis signaling in cancer cells by upregulating different pro-apoptotic signaling molecules, such as BAX, CASP9, and CASP3, and downregulating the anti-apoptotic protein BCL2 (101) . EVs treatment exhibited the reduced viability of ovarian cancer cells. Additionally, sequencing of EV-RNAs revealed a rich population of miRNAs, which exhibit anti-cancer activities by targeting different molecules associated with cancer survival (102) . These findings are in agreement with previously reported tumor inhibitory activities of AD-MSC derived EVs (101) . In fact, miR-145 from AD-MSC derived EVs could extend the inhibitory effects of MSCs on prostate cancer by blocking the activities of anti-apoptotic Bclxl protein, followed by increased cell apoptosis of prostate cancer cells (101) .
EVs-mediated delivery of selective miRNAs from HLSCs may reprogram HepG2 hepatoma and primary hepatocellular carcinoma cells by inhibiting their growth and survival in vitro (103) . In vivo intra-tumor administration and uptake of HLSC-EVs in severe combined immune deficiency (SCID) mice may induce regression of ectopic tumors developed through the delivery of miRNAs to tumor cells. The antitumor effect of HLSC-EVs and miRNA delivery was also observed in tumors other than hepatoma such as lymphoblastoma and glioblastoma, which showed that the delivery of selected miRNAs by stem cell-EVs efficiently inhibits tumor growth and may stimulate apoptosis (103) .
Fareh et al. has shown that primary glioma cells transport miR-302-367 to neighboring GBM cells via EVs, which could modulate the expression of stemness markers, as well as the proliferation and the tumorigenicity of recipient GBM cells (104) . Importantly, EV-mediated transfer of miR-302-367 elicited the inhibition of its targets such as CXCR4/SDF1, SHH, cyclin D, cyclin A and E2F1 in recipient GBM cells indicating their effect on cell cycle inhibition. Furthermore, the orthotopic xenograft of miR-302-367-expressing cells together with GSCs efficiently altered the tumor development in mice brain (104) . This indicates that EVs could be exploited as vectors of cell cycle inhibition in cancer cells. MSCs transfected with miR-146b produce EVs loaded with exogenous miR-146b; whereas, intra-tumor injection of miR-146 containing EVs could significantly reduce glioma xenograft growth in a rat model of primary brain tumor (105) . MSC-derived EVs transfer miR-100 to breast cancer cells which down-regulates VEGF expression (106) . Moreover, downregulation of VEGF expression by MSC-derived EV-miR-100 could affect the vascular behavior of endothelial cells in vitro. This indicates that EV-mediated transfer of miR-100 to cancer cells paracrine effects of MSC-derived EVs in modulating vascular responses (angiogenesis) within the microenvironment of cancer cells, thus offering a vector of targeting cancer angiogenesis.
EVs derived from menstrual stem cells (MenSCs) are capable to inhibit prostate tumor through inhibiting reactive oxygen species (ROS) (107) . In fact, the endometrial cells are fine regulators of the angiogenic process during the menstrual cycle that includes an angiostatic condition. EVs from MenSCs could induce a reduction in VEGF secretion and NF-κB activity in prostate cancer cells. The ROS production was reduced in EV-treated cells, suggesting that the inhibition of the intracellular ROS influences both VEGF and NF-κB pathways (including the inhibition of VEGF and HIF-1α expression). This indicates that the MenSCs-EVs suppress the secretion of pro-angiogenic factors by prostate cancer cells in a ROS-dependent manner. Importantly, the anti-angiogenic effect of EVs is specific to the menstrual cell source, as the BMMSCderived EVs showed an opposite effect on the VEGF and bFGF expression in tumor cells. Since the MenSCs-derived EVs act as blockers of the tumor-induced angiogenesis, therefore they could be suitable candidates for anti-cancer therapies. In a previous study, MSC-derived EVs were shown to significantly down-regulate the VEGF expression in tumor cells, which lead to inhibition of angiogenesis in vitro and in vivo (108) . It was shown that MSC-derived EVs are enriched in anti-angiogenic miRNA-16 that is internalized by breast cancer cells and suppress VEGF expression thereby favoring the inhibition of angiogenesis in recipient tumor cells.
Concluding remarks
EVs secreted from MSCs, cancer-like stem cells, and cancer cells actively disseminate biologically active cargos, which could facilitate tumor progression directly or through relaying bystander effects. The tumor promoting activities are shared between normal stem cells of various tissue origins, cancer stem like-cells (i.e., CSCs), and cancer cells in an intricate intratumoral network to create selfstrengthening tumor niche, where EV-ncRNAs serve as mediators to transmit bystander effects of secreting cells into recipient cells for priming a conducive environment. It could be speculated that EV-based cancer-initiating activities of CSCs (i.e., identification of cancer initiating cells-CICs), and functional enrichment could add a layer of valuable knowledge to explain cancer-initiating models (1) . In this context, CSC-subpopulation specific EV-ncRNAs could contribute new knowledge for resolving the existing controversies in cancer-initiating activities and enrichment, which are hotly debated issues in CSC model and the stochastic cancer model.
Given that the MSC-derived or cancer cell-derived EV-ncRNAs facilitate positive feedback loop between cancer cells and MSCs to create a tumor permissive microenvironment; this knowledge could be a potential target to create a suppressive microenvironment for targeting tumor growth. Indeed, EVs are efficient biological vehicles of cargo delivery between cells. This indicates that EVs, particularly MSC-derived EVs could be engineered for the delivery of anti-cancer drugs and genes (antagonistic miRNAs or siRNA) for CSC targeting therapy or MSC-based targeting therapies for monitoring cancer pathways (66) . However, the procedures of obtaining EVs from desired sources for therapeutic purposes need robust and sensitive capture techniques and the endorsement of therapeutic potencies of EVs in clinical settings needs rigorous validation in model animals.
